不同剂量利拉鲁肽对新诊断腹型肥胖2型糖尿病患者运动耐量的研究被引量：9

下载PDF

导出

摘要近年来,胰升血糖素1（GLP-1）类似物利拉鲁肽的问世,为临床治疗初诊腹型肥胖2型糖尿病带来了新方向。据研究显示,该药物不仅能够有效控制患者血糖,同时对于减少患者体质量、改善其运动耐量具有积极的作用。但不同剂量的利拉鲁肽其疗效也不尽相同。因此,为探究不同剂量利拉鲁肽对初诊腹型肥胖2型糖尿病患者的治疗效果.

作者吴晓谦谷林德林群力

机构地区浙江省永嘉县人民医院内分泌科浙江省永嘉县人民医院工会浙江省永嘉县人民医院神经内科

出处《中国药物与临床》 CAS 2018年第6期933-935,共3页 Chinese Remedies & Clinics

基金中华人民共和国科技部"十二五"国家科技支撑计划[2011BAI08A03]

关键词腹型肥胖2型糖尿病利拉鲁肽运动耐量患者剂量胰升血糖素诊断治疗效果

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献4

1宋丹,刘爽,李继业.利拉鲁肽对初诊肥胖2型糖尿病合并非酒精性脂肪肝的疗效观察[J].河南医学研究,2017,26(12):2139-2140. 被引量：4
2张萍,潘天荣,钟兴,杜益君.利拉鲁肽联合胰岛素治疗新诊断肥胖2型糖尿病的临床疗效及安全性观察[J].中国糖尿病杂志,2014,22(11):974-977. 被引量：47
3逯勇,高璨,梁辰,常晓红,武宝梅,马云.原发性高血压患者运动耐量研究[J].中国运动医学杂志,2014,33(11):1043-1046. 被引量：7
4丁丽萍.利拉鲁肽治疗不同病程肥胖/超重2型糖尿病患者的临床疗效及安全性观察[J].中国医药指南,2016,14(25):81-82. 被引量：5

二级参考文献31

1Yang W,Lu J,Jia WJ,et al.Prevalence of diabetes among men and women in China.N Engl J Med,2010,362:1090-1101.
2Marre M,Shaw J,Brandle M,et al.Liraglulide,a once-daily human GLP-1 analogue,added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU).Diabet Med,2009,26:268-278.
3Nauck M,Frid A,Hermansen K,et al.Efficacy and safety comparison of liraglutide,glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD(liraglutide effect and action in diabetes)-2 study.Diabetes Care,2009,32:84-90.
4Zinman B,Gerich J,Buse JB,et al.Efficacy and safety of the human glueagon glueago likepeptide-1 analog liraglutide in combination with metfornin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+ TZD).Diabetes Care,2009,32:1224-1230.
5Russell-Jones D,Vaag A,Schmitz O,et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU):a randomised controlled trial.Diabetologia,2009,52:2046-2055.
6Finucane MM,Stevens GA,Cowan MJ,et al.National,regional,and global trends in body-mass index since 1980:systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants.Lancet,2011,377:557-567.
7Perfetti R.Combining basal insulin analogs with glucagon-like peptide-1 mimetics.Diabetes Technol Ther,2011,13:873-881.
8Cohen ND,Audehm R,Pretorius E,et al.The rationale for Combining GLP-1 receptor agonists with basal insulin.Med J Aust,2013,19:246-249.
9Berlie H,Hurren KM,Pinelli NR.Glucagon-like Peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes:a systematic review.Diabetes Metab Syndr Obes,2012,5:165-174.
10Li CJ,Li J,Zhang QM,et al.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.Cardiovasc Diabetol,2012,11:142.